Table 2 |
||
|
Appraisal of the internal validity of the QALY-endpoint in six cost-utility studies in the HTA on dementia drugs [56] |
||
|
Product assessed (study) |
Internal validity |
Comment on generation of QALYs |
|
|
||
|
Donepezil [58] |
Unacceptable |
Based on the Index of Health Related Quality of Life (IHQL) which was not validated for valuing cognitive impairment, and no rationale was given for the IHQL values used |
|
Donepezil [59] |
Unclear or unknown |
Not stated |
|
Rivastigmine [60] |
Unacceptable |
Based on the IHQL (see above) |
|
Unclear or unknown |
Derived from [63] (pre – full time care at 0.60, full time care at 0.34) |
|
|
Memantine [64] |
Unclear or unknown/unacceptable |
Insufficient detail found in the study |
|
|
||
|
Riepe et al. BMC Neurology 2009 9:47 doi:10.1186/1471-2377-9-47 |
||
